Abstract: The present invention provides synthetic peptides comprising at least analogues of a native peptide that specifically bind to HLA A0201 or HLA A0301 molecules on a cell characteristic of a pathophysiologic state, such as a cancer cell, in a mammal. Also provided are pharmaceutical compositions and immunogenic compositions comprising at least the peptide analogue segments or a DNA encoding the same. Also provided are methods of using the synthetic peptides and immunogenic compositions to induce a heteroclitic immune response or to treat a cancer.
Type:
Grant
Filed:
November 30, 2004
Date of Patent:
February 10, 2009
Assignee:
Sloan Kettering Institue for Cancer Research